Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 112, Issue -, Pages 155-163Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2016.11.015
Keywords
Polyglutamic acid; PEGylated polyglutamic acid; Nanocapsules; Biodistribution; Lymphatic targeting
Categories
Funding
- European Commission FP7 [PS09/02670]
- NICHE projects (ERA-NET EuroNanoMed II framework by ISCIII through CIBER-BBN)
- Xunta de Galicia (Isidro Parga Pondal Fellowship and Competitive Reference Groups-FEDER Funds) [GRC2013-043]
- Doctoral School of Biomedical Sciences and Health Technologies - University of Santiago de Compostela
Ask authors/readers for more resources
Recently we reported the development of 100 nm polyglutamic acid (PGA)-based nanocapsules, which were intended to carry anticancer drugs to the lymphatic system (Abellan-Pose et al., 2016). In this work, the objective was to further assess the potential Iympho-targeting properties of radiolabeled In-111-PGA and In-111-PGA-PEG, following intravenous or subcutaneous administration. The results indicate that, following intravenous administration, both types of nanocapsules exhibit a modest accumulation in the lymph nodes (<= 2.3% ID/g). On the contrary, following subcutaneous administration, and irrespective of the presence of PEG on their surface, the nanocapsules were found to form a reservoir at the injection site, from which they drained slowly into the popliteal and the iliac lymph nodes. The significant accumulation of the radiolabeled nanocapsules in the lymph nodes was attained at 24 and 48 h post-injection, reaching values comprised between 70% and 187% 'Dig in the popliteal lymph nodes. Altogether, the results led us to validate our hypothesis about the ability of the PGA and PGA-PEG nanocapsules to reach the lymphatic system, especially following subcutaneous administration. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available